Differential effects on lung cancer cell proliferation by agonists of glucocorticoid and PPARα receptors

Huiyun Liang, Piotr Kowalczyk, Jacob J. Junco, Heather L. Klug-De Santiago, Gunjan Malik, Sung Jen Wei, Thomas J Slaga

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Glucocorticoids (GCs) are well-known anti-inflammatory compounds, but they also inhibit cell proliferation depending on cell type. Similarly, peroxisome proliferator-activated receptors (PPARα, PPARδ, and PPARγ) also possess anti-proliferation properties beyond their canonical roles as metabolic mediators. In the present study, we investigated the potential additive or synergistic inhibitory effects on cancer cell proliferation by simultaneous application of fenofibrate and budesonide, agonists for PPARα and glucocorticoid receptor, respectively. We observed differential effects on cell proliferation in A549 and SK-MES-1 lung cancer cells by budesonide and fenofibrate. Fenofibrate inhibited cell proliferation in both TP53 wild type and deficient lung cancer cells. The anti-proliferation effect of budesonide in TP53 wild type A549 cells was abolished in SK-MES-1 cells that do not have wild type TP53 protein. An additive effect against cell proliferation by budesonide and fenofibrate combination was observed only in TP53 wild type A549 cancer cells. Analysis of cell cycle distribution and cyclin profile indicated that the inhibition of cell proliferation was associated with G1 cell cycle arrest. The suppression of NF-κB activity and ERK signaling may contribute to the inhibition of cell proliferation by budesonide and or fenofibrate. The additive inhibitory effect on cell proliferation by budesonide and fenofibrate combination suggests that the same or greater therapeutic effect could be achieved with reduced dosage and side effects when the two compounds are applied simultaneously.

Original languageEnglish (US)
Pages (from-to)753-763
Number of pages11
JournalMolecular Carcinogenesis
Volume53
Issue number9
DOIs
StatePublished - 2014

Fingerprint

Peroxisome Proliferator-Activated Receptors
Glucocorticoid Receptors
Fenofibrate
Budesonide
Lung Neoplasms
Cell Proliferation
G1 Phase Cell Cycle Checkpoints
Tumor Suppressor Protein p53
Cyclins
Therapeutic Uses
Glucocorticoids
Neoplasms
Cell Cycle
Anti-Inflammatory Agents

Keywords

  • Budesonide
  • Fenofibrate
  • Glucocorticoid receptor (GR)
  • Lung cancer
  • Peroxisome proliferator-activated receptor α (PPARα)

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology
  • Medicine(all)

Cite this

Differential effects on lung cancer cell proliferation by agonists of glucocorticoid and PPARα receptors. / Liang, Huiyun; Kowalczyk, Piotr; Junco, Jacob J.; Klug-De Santiago, Heather L.; Malik, Gunjan; Wei, Sung Jen; Slaga, Thomas J.

In: Molecular Carcinogenesis, Vol. 53, No. 9, 2014, p. 753-763.

Research output: Contribution to journalArticle

Liang, H, Kowalczyk, P, Junco, JJ, Klug-De Santiago, HL, Malik, G, Wei, SJ & Slaga, TJ 2014, 'Differential effects on lung cancer cell proliferation by agonists of glucocorticoid and PPARα receptors', Molecular Carcinogenesis, vol. 53, no. 9, pp. 753-763. https://doi.org/10.1002/mc.22029
Liang, Huiyun ; Kowalczyk, Piotr ; Junco, Jacob J. ; Klug-De Santiago, Heather L. ; Malik, Gunjan ; Wei, Sung Jen ; Slaga, Thomas J. / Differential effects on lung cancer cell proliferation by agonists of glucocorticoid and PPARα receptors. In: Molecular Carcinogenesis. 2014 ; Vol. 53, No. 9. pp. 753-763.
@article{1267459b730c415295e520f758a01516,
title = "Differential effects on lung cancer cell proliferation by agonists of glucocorticoid and PPARα receptors",
abstract = "Glucocorticoids (GCs) are well-known anti-inflammatory compounds, but they also inhibit cell proliferation depending on cell type. Similarly, peroxisome proliferator-activated receptors (PPARα, PPARδ, and PPARγ) also possess anti-proliferation properties beyond their canonical roles as metabolic mediators. In the present study, we investigated the potential additive or synergistic inhibitory effects on cancer cell proliferation by simultaneous application of fenofibrate and budesonide, agonists for PPARα and glucocorticoid receptor, respectively. We observed differential effects on cell proliferation in A549 and SK-MES-1 lung cancer cells by budesonide and fenofibrate. Fenofibrate inhibited cell proliferation in both TP53 wild type and deficient lung cancer cells. The anti-proliferation effect of budesonide in TP53 wild type A549 cells was abolished in SK-MES-1 cells that do not have wild type TP53 protein. An additive effect against cell proliferation by budesonide and fenofibrate combination was observed only in TP53 wild type A549 cancer cells. Analysis of cell cycle distribution and cyclin profile indicated that the inhibition of cell proliferation was associated with G1 cell cycle arrest. The suppression of NF-κB activity and ERK signaling may contribute to the inhibition of cell proliferation by budesonide and or fenofibrate. The additive inhibitory effect on cell proliferation by budesonide and fenofibrate combination suggests that the same or greater therapeutic effect could be achieved with reduced dosage and side effects when the two compounds are applied simultaneously.",
keywords = "Budesonide, Fenofibrate, Glucocorticoid receptor (GR), Lung cancer, Peroxisome proliferator-activated receptor α (PPARα)",
author = "Huiyun Liang and Piotr Kowalczyk and Junco, {Jacob J.} and {Klug-De Santiago}, {Heather L.} and Gunjan Malik and Wei, {Sung Jen} and Slaga, {Thomas J}",
year = "2014",
doi = "10.1002/mc.22029",
language = "English (US)",
volume = "53",
pages = "753--763",
journal = "Molecular Carcinogenesis",
issn = "0899-1987",
publisher = "Wiley-Liss Inc.",
number = "9",

}

TY - JOUR

T1 - Differential effects on lung cancer cell proliferation by agonists of glucocorticoid and PPARα receptors

AU - Liang, Huiyun

AU - Kowalczyk, Piotr

AU - Junco, Jacob J.

AU - Klug-De Santiago, Heather L.

AU - Malik, Gunjan

AU - Wei, Sung Jen

AU - Slaga, Thomas J

PY - 2014

Y1 - 2014

N2 - Glucocorticoids (GCs) are well-known anti-inflammatory compounds, but they also inhibit cell proliferation depending on cell type. Similarly, peroxisome proliferator-activated receptors (PPARα, PPARδ, and PPARγ) also possess anti-proliferation properties beyond their canonical roles as metabolic mediators. In the present study, we investigated the potential additive or synergistic inhibitory effects on cancer cell proliferation by simultaneous application of fenofibrate and budesonide, agonists for PPARα and glucocorticoid receptor, respectively. We observed differential effects on cell proliferation in A549 and SK-MES-1 lung cancer cells by budesonide and fenofibrate. Fenofibrate inhibited cell proliferation in both TP53 wild type and deficient lung cancer cells. The anti-proliferation effect of budesonide in TP53 wild type A549 cells was abolished in SK-MES-1 cells that do not have wild type TP53 protein. An additive effect against cell proliferation by budesonide and fenofibrate combination was observed only in TP53 wild type A549 cancer cells. Analysis of cell cycle distribution and cyclin profile indicated that the inhibition of cell proliferation was associated with G1 cell cycle arrest. The suppression of NF-κB activity and ERK signaling may contribute to the inhibition of cell proliferation by budesonide and or fenofibrate. The additive inhibitory effect on cell proliferation by budesonide and fenofibrate combination suggests that the same or greater therapeutic effect could be achieved with reduced dosage and side effects when the two compounds are applied simultaneously.

AB - Glucocorticoids (GCs) are well-known anti-inflammatory compounds, but they also inhibit cell proliferation depending on cell type. Similarly, peroxisome proliferator-activated receptors (PPARα, PPARδ, and PPARγ) also possess anti-proliferation properties beyond their canonical roles as metabolic mediators. In the present study, we investigated the potential additive or synergistic inhibitory effects on cancer cell proliferation by simultaneous application of fenofibrate and budesonide, agonists for PPARα and glucocorticoid receptor, respectively. We observed differential effects on cell proliferation in A549 and SK-MES-1 lung cancer cells by budesonide and fenofibrate. Fenofibrate inhibited cell proliferation in both TP53 wild type and deficient lung cancer cells. The anti-proliferation effect of budesonide in TP53 wild type A549 cells was abolished in SK-MES-1 cells that do not have wild type TP53 protein. An additive effect against cell proliferation by budesonide and fenofibrate combination was observed only in TP53 wild type A549 cancer cells. Analysis of cell cycle distribution and cyclin profile indicated that the inhibition of cell proliferation was associated with G1 cell cycle arrest. The suppression of NF-κB activity and ERK signaling may contribute to the inhibition of cell proliferation by budesonide and or fenofibrate. The additive inhibitory effect on cell proliferation by budesonide and fenofibrate combination suggests that the same or greater therapeutic effect could be achieved with reduced dosage and side effects when the two compounds are applied simultaneously.

KW - Budesonide

KW - Fenofibrate

KW - Glucocorticoid receptor (GR)

KW - Lung cancer

KW - Peroxisome proliferator-activated receptor α (PPARα)

UR - http://www.scopus.com/inward/record.url?scp=84906097404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906097404&partnerID=8YFLogxK

U2 - 10.1002/mc.22029

DO - 10.1002/mc.22029

M3 - Article

C2 - 23625588

AN - SCOPUS:84906097404

VL - 53

SP - 753

EP - 763

JO - Molecular Carcinogenesis

JF - Molecular Carcinogenesis

SN - 0899-1987

IS - 9

ER -